摘要
目的探讨血清N端骨钙素(N-Osrteoc)、骨桥蛋白(OPN)、前列腺特异性抗原(PSA)联合检测在前列腺癌骨转移诊断中的价值。方法将2016年1月至2020年4月中国人民解放军陆军第八十一集团军医院收治的93例前列腺癌患者纳入研究,根据核素骨显像检查结果分为无骨转移组(40例)和骨转移组(53例)。采用罗氏CobasE411全自动电化学分析仪检测血清N-Osrteoc水平,贝克曼Access2全自动化学发光分析仪检测血清PSA水平,酶联免疫吸附法(ELISA)检测血清OPN水平,应用受试者工作特征(ROC)曲线评价上述指标用于前列腺癌骨转移诊断的价值。结果骨转移组患者血清N-Osrteoc、OPN、PSA水平均高于无骨转移组(P<0.05)。无骨转移组与骨转移组肿瘤最大径、TNM分期、浸润深度、复发与否比较,差异有统计学意义(P<0.05),且骨转移组中肿瘤最大径≥5 cm、TNM分期Ⅲ~Ⅳ期、浸润深度≥6 cm、有复发的患者比例明显高于无骨转移组(P<0.05)。血清N-Osrteoc、OPN、PSA联合检测用于前列腺癌骨转移诊断的曲线下面积(AUC)、灵敏度、特异度、准确度分别为0.873、88.7%、92.5%和90.3%,均高于血清N-Osrteoc、OPN、PSA三者单独检测(P<0.05)。多因素Logistic回归分析显示:TNM分期Ⅲ~Ⅳ期、高水平N-Osrteoc、OPN、PSA是前列腺癌骨转移的独立危险因素(P<0.05)。结论前列腺癌骨转移患者血清N-Osrteoc、OPN、PSA水平明显升高;N-Osrteoc、OPN联合PSA检测在前列腺癌骨转移诊断中具有较高的灵敏度、特异度,值得临床推广应用。
Objective To investigate the value of combined detection of serum N-terminal osteocalcin(N-Osrteoc),osteopontin(OPN)and prostate-specific antigen(PSA)in the diagnosis of prostate cancer bone metastases.Methods Ninety-three patients with prostate cancer who were admitted to the 81st Group Army Hospital of the PLA from January 2016 to April 2020 were enrolled in the study.According to the results of radionuclide bone scintigraphy,they were divided into non-bone metastasis group(40 cases)and bone metastasis group(53 cases).Serum N-Osrteoc level was detected by Roche CobasE411 automatic electrochemical analyzer,serum PSA level was detected by Beckman Access2 automatic chemiluminescence analyzer,and serum OPN level was detected by using enzyme-linked immunosorbent assay(ELISA).The receiver operating characteristic(ROC)curve was used to evaluate the diagnostic value of the above indicators for bone metastasis of prostate cancer.Results The serum levels of N-Osrteoc,OPN and PSA in the bone metastasis group were higher than those in the non-bone metastasis group(P<0.05).There were significant differences in the maximum tumor diameter,TNM stage,depth of invasion,and recurrence between the non-bone metastasis group and the bone metastasis group(P<0.05).The proportions of patients with tumor diameter≥5 cm,TNM stageⅢ-Ⅳ,depth of invasion≥6 cm,and recurrence in the bone metastasis group was significantly higher than those in the non-bone metastasis group(P<0.05).The area under the curve(AUC),sensitivity,specificity and accuracy of serum N-Osrteoc,OPN and PSA combined detection for bone metastases of prostate cancer were 0.873,88.7%,92.5%and 90.3%,respectively,which were higher than those of serum N-Osrteoc,OPN and PSA detected alone(P<0.05).Multivariate Logistic regression analysis showed that TNM stageⅢ-Ⅳ,high levels of N-Osrteoc,OPN and PSA were independent risk factors for bone metastasis of prostate cancer(P<0.05).Conclusion The serum levels of N-Osrteoc,OPN and PSA in patients with bone metastases of prostate
作者
张春霞
管华
郭连洪
李伟
孙建伟
郭建明
ZHANG Chunxia;GUAN Hua;GUO Lianhong;LI Wei;SUN Jianwei;GUO Jianming(Department of Laboratory and Pathology,the 81st Group Army Hospital of the PLA,Zhangjiakou,Hebei 075000,China;Department of Clinical Laboratory,Zhangjiakou Maternal and Child Health Hospital,Zhangjiakou,Hebei 075000,China;Department of Nuclear Medicine,Zhangjiakou First Hospital,Zhangjiakou,Hebei 075000,China;Department of Oncology,the 81st Group Army Hospital of the PLA,Zhangjiakou,Hebei 075000,China)
出处
《国际检验医学杂志》
CAS
2022年第7期810-813,共4页
International Journal of Laboratory Medicine
基金
张家口市重点研发计划项目(2021097D)。
关键词
N端骨钙素
骨桥蛋白
前列腺特异性抗原
前列腺癌
骨转移
N-terminal osteocalcin
osteopontin
prostate specific antigen
prostate cancer
bone metastasis
